Human PARK7 Matched Antibody Pair Kit (DJ1) (ab218797)
Key features and details
- Unlabeled capture antibody, biotin-labeled detection antibody and calibrated protein standard
- For economical ELISA and ELISA-based assay development
- Reacts with: Human
- Range: 312.5 pg/ml - 20000 pg/ml
Overview
-
Product name
Human PARK7 Matched Antibody Pair Kit (DJ1)
See all PARK7/DJ1 kits -
Detection method
Colorimetric -
Assay type
ELISA set -
Sensitivity
76.4 pg/ml -
Range
312.5 pg/ml - 20000 pg/ml -
Species reactivity
Reacts with: Human -
Product overview
Human PARK7 Matched Antibody Pair Kits include a capture and a biotinylated detector antibody pair, along with a calibrated protein standard, suitable for sandwich ELISA. The Matched Antibody Pair Kit can be used to quantify native and recombinant human PARK7.
Optimization of the kit reagents to sample type, immunoassay format or instrumentation may be required. Guidelines for use of this kit in a standard 96-well microplate sandwich ELISA using HRP/TMB system of colorimetric detection is described in this assay procedure for the purposes of quantification.
Protocol information and tips on the use of the Matched Antibody Pair kits for sandwich ELISA can be found on our website. An accessory pack can be purchased which includes buffer reagents required to perform 10 x 96-well plate sandwich ELISAs (ab210905).
For additional information on the performance of the antibody pair used in this kit, please see our equivalent SimpleStep ELISA kit ab215535. Please note that while the antibody pair is the same provided in the corresponding SimpleStep ELISA Kit, due to differences in their formulation, this antibody pair cannot be used with the consumables provided with our SimpleStep ELISA Kits.
-
Tested applications
Suitable for: ELISAmore details -
Platform
Reagents
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 10 x 96 tests 5 x 96 tests Human PARK7 Capture Antibody 2 x 50µg 1 x 50µg Human PARK7 Detector Antibody 2 x 12.5µg 1 x 12.5µg Human PARK7 Lyophilized Protein 2 vials 1 vial -
Research areas
-
Function
Protects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria. Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone. -
Tissue specificity
Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. -
Involvement in disease
Defects in PARK7 are the cause of Parkinson disease type 7 (PARK7) [MIM:606324]. A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease). -
Sequence similarities
Belongs to the peptidase C56 family. -
Post-translational
modificationsSumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.
Cys-106 is easily oxidized to sulfinic acid.
Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress. -
Cellular localization
Cytoplasm. Nucleus. Mitochondrion. Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients. - Information by UniProt
-
Alternative names
- CAP1
- DJ-1
- DJ1
see all -
Database links
- Entrez Gene: 11315 Human
- Omim: 602533 Human
- SwissProt: Q99497 Human
- Unigene: 419640 Human
Images
-
Human PARK7 standard curve
Standard calibration curve. Background subtracted values are graphed.
-
Sandwich ELISA - Human PARK7 Matched Antibody Pair Kit (DJ1) (ab218797)To learn more about the advantages of recombinant antibodies see here.
